Lupin yesterday launched Droxidopa capsules, 100 mg, 200 mg and 300 mg, having received an approval from the United States Food and Drug Administration (USFDA).
The product is manufactured at Lupin’s facility in Nagpur, India, according to a statement released by the company.
Droxidopa Capsules, 100 mg, 200 mg and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg and 300 mg, of Lundbeck NA.
It is indicated for the treatment of orthostatic dizziness, light headedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa Capsules had estimated annual sales of $294 million in the US, according to IQVIA, added the statement.
Sun Pharma launches a novel formulation for Cough management
Lincoln Pharma plans to launch Cephalosporin products
Natural Antioxidant Gamma Oryzanol launched in India
Dr. Reddy’s Labs launches Rx drug Minoxidil for treatment of hair
Dr Reddy’s launches Reddy-Lenalidomide
Lupin launches drug for Asthma patient
DCGI allows Serum Institute for Vaccine trial on kids aged…
Telangana sees huge expansion in Drug Manufacturing
Sun Pharma launches a novel formulation for Cough management
Pfizer to soon submit data on C-19 vaccine for kids aged…
Practical training to Pharmacy Students in industrial units
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
